Navigation Links
Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
Date:5/7/2011

European pathogens commonly isolated in CABP and ABSSSI.  

Farrell et al. (Abst. P1452) investigated the activity of solithromycin against almost 1,200 H. influenzae strains acquired from patients with CABP in 24 countries as part of the SENTRY antimicrobial surveillance program from 2009.  Solithromycin had greater potency than telithromycin, with MIC50 and MIC90 values of one and two micrograms/mL, respectively. Solithromycin resistance, found in nine of the 1,198 isolates (less than one percent), was rare, and when observed was attributed to ribosomal gene mutations.

TAKSTA (CEM-102, sodium fusidate)

TAKSTA is sodium fusidate delivered with a proprietary front-loading dosing regimen to enhance spectrum of activity, optimize efficacy and reduce resistance development.  Sodium fusidate has a long and established record of safety and efficacy outside the U.S.  Jones et al. (Abst. P944) evaluated the activity of fusidic acid against over 16,000 contemporary gram positive pathogens associated with ABSSSI isolated in the U.S. from 2008 to 2010.  Twelve thousand of these strains were S. aureus, of which 52 percent were MRSA; 2,000 strains were coagulase-negative staphylococci (CoNS); and 2,000 were beta-haemolytic streptococci (group A and B).  Fusidic acid was highly active against all ABSSSI strains including S. aureus (99.73 percent at less than 1 micrograms/mL), with both methicillin-sensitive and MRSA strains having similar sensitivity rates.  Methicillin-resistant CoNS was slightly less sensitive (90.76 percent) than methicillin-sensitive CoNS (97.28 pe
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
2. New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Reportlinker Adds Global Intravenous (IV) Iron Drugs Industry
5. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
6. Reportlinker Adds Intravenous Equipment - A World Market Intelligence Report
7. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
8. Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
9. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
10. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Calif., Dec. 17 PEAK Surgical, Inc., a ... dissection system based on a,proprietary technology, announced today ... granted the company 510(k) clearance to market its,PEAK(R) ... tissue during,plastic and reconstructive, ENT (ear, nose and ...
... Calif., Dec. 17 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... independent,Data Safety Monitoring Board (DSMB) has determined that ... of acute ischemic stroke are unlikely,to show benefit. ... enrollment in,the trials. NTI will obtain and analyze ...
Cached Medicine Technology:PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 4Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... Is Not Safe for Everyone , Not all ... epirubicin. New models can help physicians calculate the epirubicin ... for individual patients. , Oncologists frequently use anthracyclines, including ... the drugs cause lasting heart problems in a substantial ...
... percent sequentially - Q2 GAAP net profit of ... - Case shipments of 54,870 increase 6.0 percent sequentially ... CLARA, Calif., July 29 Align,Technology, Inc. (Nasdaq: ALGN ) ... June 30, 2008., Total net revenues for the second quarter ...
... ceramic implantable components surpasses projected ... ... Medical Werks, a manufacturer of,high-quality ceramic solutions for the medical device ... millionth ceramic,implantable component based on unit shipments to the orthopaedic,brachytherapy and ...
... Benjamin, MD, FACP, FACEP (E), Executive,Director, American Public ... American Public,Health Association strongly urges U.S. House members ... give the Food and Drug Administration (FDA),the authority ... is responsible for more than 400,000 deaths each,year ...
... matted protein, researchers say , , TUESDAY, July 29 (HealthDay News) ... "tangles" in the brain cells of people with Alzheimer,s disease ... are necessary to confirm whether the medication is as effective ... to be given as part of a cocktail of treatments. ...
... New Jersey Health Care Quality Institute Announces Results of Milken ... Institute Study Future Costs Can ... ... a groundbreaking study,released by the Milken Institute, the annual economic impact on New,Jersey,s economy of ...
Cached Medicine News:Health News:Also in the July 29 JNCI 2Health News:Also in the July 29 JNCI 3Health News:Also in the July 29 JNCI 4Health News:Also in the July 29 JNCI 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 2Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 3Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 4Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 6Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 7Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 8Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 9Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 10Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 11Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 12Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 13Health News:C5 Medical Werks Reaches Million Mark in Components Shipped 2Health News:'De-Tangling' Alzheimer's Drug Shows Promise 2Health News:'De-Tangling' Alzheimer's Drug Shows Promise 3Health News:'De-Tangling' Alzheimer's Drug Shows Promise 4Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 2Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 3Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... advanced nutritional formulation that provides powerful ... health. MacularProtect Complete-S, based on the ... research, delivers a diverse array of ... FloraGLO® lutein and other important nutrients. ...
Medicine Products: